Transcat, Inc. (NASDAQ:TRNS) Stock Has Consensus Target Price of $108.33

Transcat, Inc. (NASDAQ:TRNS) has been assigned a consensus recommendation of “Hold” from the five brokerages that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $108.33.

TRNS has been the subject of several analyst reports. CJS Securities initiated coverage on Transcat in a research note on Tuesday, October 27th. They set an “outperform” rating and a $115.00 price target for the company. Oppenheimer raised shares of Transcat from a “market perform” rating to an “outperform” rating and set a $115.00 price target for the company in a report on Wednesday. Northland Securities raised Transcat from a “market perform” rating to an “outperform” rating and set a $95.00 price objective on the stock in a report on Wednesday, October 21st. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Transcat in a research report on Tuesday, August 25th.

Transcat Stock Performance

NASDAQ TRNS opened at $89.52 on Wednesday. The firm has a market cap of $840.59 million, a P/E ratio of 241.95 and a beta of 0.61. Transcat has a 52-week low of $50.23 and a 52-week high of $100.00. The business’s 50-day moving average price is $86.10 and its 200 day moving average price is $81.83. The company has a quick ratio of 2.11, a current ratio of 2.49 and a debt-to-equity ratio of 0.36.

Transcat (NASDAQ:TRNS) last posted its quarterly earnings data on Tuesday, November 3rd. The scientific and technical instruments company reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.45 by $0.19. Transcat had a return on equity of 5.56% and a net margin of 0.99%. The company had revenue of $97.09 million during the quarter, compared to analysts’ expectations of $92.46 million. On average, equities research analysts expect that Transcat will post 1.79 earnings per share for the current year.

Insider Buying and Selling

In other Transcat news, Director Craig Cairns acquired 1,050 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The shares were purchased at an average price of $93.97 per share, with a total value of $98,668.50. Following the completion of the acquisition, the director directly owned 1,480 shares of the company’s stock, valued at approximately $139,075.60. The trade was a 244.19% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Christopher P. Gillette sold 504 shares of the company’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $94.23, for a total value of $47,491.92. Following the transaction, the director directly owned 200 shares in the company, valued at $18,846. This represents a 71.59% decrease in their position. The disclosure for this sale is available in the SEC filing. 1.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Transcat

Several hedge funds have recently modified their holdings of the stock. Integrated Wealth Concepts LLC purchased a new position in Transcat in the 2nd quarter worth approximately $32,000. Persistent Asset Partners Ltd purchased a new stake in shares of Transcat during the second quarter valued at approximately $52,000. GAMMA Investing LLC raised its stake in shares of Transcat by 133.6% during the third quarter. GAMMA Investing LLC now owns 1,030 shares of the scientific and technical instruments company’s stock valued at $91,000 after purchasing an additional 589 shares during the period. Canada Pension Plan Investment Board acquired a new position in shares of Transcat during the second quarter worth $204,000. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Transcat during the second quarter worth $226,000. 98.34% of the stock is currently owned by hedge funds and other institutional investors.

More Transcat News

Here are the key news stories impacting Transcat this week:

• Positive Sentiment: Transcat earned $0.64 per share, up from $0.44 a year earlier and above consensus estimates of roughly $0.42–$0.45. Revenue was $97.09 million, topping the $92.46 million estimate. Zacks earnings report
• Positive Sentiment: The company raised its fiscal 2027 outlook for service organic growth to the low double digits and is targeting at least 100 basis points of service gross-margin expansion in the second half. That outlook points to continued demand and improving service profitability. Outlook update
• Positive Sentiment: Management characterized the quarter as strong, citing double-digit organic service revenue growth and significant service gross-margin expansion. Transcat fiscal second-quarter results

Transcat Company Profile

Transcat, Inc (NASDAQ: TRNS) provides calibration, compliance, and measurement services for organizations that rely on accurate test and measurement equipment. The company supports customers in regulated industries, including life sciences, aerospace and defense, energy, manufacturing, and other industrial markets.

Its service offerings include laboratory and onsite calibration, repair, validation, and asset-management services. Transcat calibrates a broad range of equipment used to measure temperature, pressure, electrical and electronic properties, radio frequency signals, dimensional characteristics, and other technical parameters.